Activation of the immune system in cancer patients

Medical and Pediatric Oncology

Volumn 34, Issue 1, 2000, Pages 1-9

  Van Gool, Stefaan W ^a,b   Van Den Hove, Ludwig ^a   Ceuppens, Jan L ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CD40 CD154 interaction; CD80 CD86 CD28 interaction; Hemato oncology; Renal cell carcinoma; Tumor immunology

Indexed keywords

CD28 ANTIGEN; CD40 ANTIGEN; CYTOKINE;

CANCER IMMUNOLOGY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOLOGIC DISEASE; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

HUMANS; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 0033957434     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(200001)34:1<1::AID-MPO1>3.0.CO;2-L     Document Type: Review

References (75)

1. Lafferty KJ, Cunningham AJ. A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975;53:27-42.
2. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
3. Lanzavecchia A. Identifying strategies for immune intervention. Science 1993;260:937-944.
4. Van Gool SW, Barcy S, Devos S, et al. CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? Res Immunol 1995; 146:183-196.
5. van Seventer GA. Roles of multiple accessory molecules in T cell activation. Curr Opin Immunol 1991;3:294-303.
6. Jenkins MK, Johnson JG. Molecules involved in T-cell costimulation. Curr Opin Immunol 1993;5:361-367.
7. Steinman RM, Young JW. Signals arising from antigen-presenting cells. Curr Opin Immunol 1991;3:361-372.
8. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-434.
9. Vandenberghe P, Ceuppens JL. Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: evidence for signal transduction through CD5. Eur J Immunol 1991;21:251-259.
10. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
11. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321-331.
12. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol 1994;6:414-419.
13. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-609.
14. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 1995;3:87-98.
15. June CH, Ledbetter JA, Gillespie MM, et al. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987;7: 4472-4481.
16. Van Gool SW, de Boer M, Ceuppens JL. CD28 ligation by mAb or B7/BB1 provides an accessory signal for the CsA-resistant generation of cytotoxic T cell activity. J Immunol 1993;150:3254-3263.
17. Van Gool SW, Kasran A, Wallays G, et al. Accessory signalling by B7-1 for T cell activation induced by anti-CD2: evidence for IL-2-independent CTL generation and CsA-resistant cytokine production. Scand J Immunol 1995;41:23-30.
18. Van Gool SW, Zhang Y, Kasran A, et al. T helper-independent activation of human CD8(+) cells: the role of CD28 costimulation. Scand J Immunol 1996;44:21-29.
19. Linsley PS, Greene JAL, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992;176:1595-1604.
20. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-988.
21. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL. CD80, CD86 and CD40 provide accessory signals in a multiple step T cell activation model. Immunol Rev 1996;153:47-83.
22. Foy TM, Aruffo A, Bajorath J, et al. Immune regulation by CD40 and its ligand gp39. Annu Rev Immunol 1996;14:591-617.
23. Kiener PA, Moran-Davis P, Rankin BM, et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917-4925.
24. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180: 1263-1272.
25. Guo Y, Wu Y, Shinde S, et al. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med 1996; 184:955-961.
26. Wu Y, Xu J, Shinde S, et al. Rapid induction of a novel costimulatory activity on B cells by CD40 ligand. Curr Biol 1995;5:1303-1311.
27. de Boer M, Kasran A, Kwekkeboom J, et al. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol 1993;23:3120-3125.
28. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998;393:474-478.
29. Van Gool SW, Ceuppens JL, Walter H, de Boer M. Synergy between cyclosporin A and a monoclonal antibody to B7 in blocking alloantigen-induced T-cell activation. Blood 1994;83:176-183.
30. Van Gool SW, de Boer M, Ceuppens JL. The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction. J Exp Med 1994;179:715-720.
31. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
32. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-673.
33. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146.
34. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996;9:532-562.
35. Seder RA, Germain RN, Linsley PS, Paul WE. CD28-mediated costimulation of interleukin 2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon γ production. J Exp Med 1994;179:299-304.
36. Smith DR, Kunkel SL, Burdick MD, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994; 145:18-25.
37. Heuttner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 1995;146:317-322.
38. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 1996;157:5512-5520.
39. Rafiq K, Kasran A, Peng X, et al. Cyclosporin-A increases interferon-gamma production by T cells when costimulated through CD28. Eur J Immunol 1998;28:1481-1491.
40. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskunde 1909;5:273-290.
41. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
42. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18:267-268.
43. Oosterwijk E, de Weijert M, van Bokhoven A, et al. Molecular characterization of the renal cell carcinoma-associated antigen G250. Proc Am Assoc Cancer Res 1996;37:A3147.
44. Mulders P, Figlin R, deKernion JB, et al. Renal cell carcinoma: recent progress and future directions. Cancer Res 1997;57:5189-5195.
45. Van den Hove LE, Van Gool SW, Van Poppel H, et al. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 1997;109:501-509.
46. Van den Hove LE, Van Gool SW, Van Poppel H, et al. Identification of an enriched CD4+ CD8α++ CD8β+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. Int J Cancer 1997;71:178-182.
47. Van den Hove LE, Symons F, Vandenberghe P, et al. Multivariate reconstruction of lymphocyte profiles in a two-dimensional graphical model as a tool for the investigation of lymphocyte subset distribution in health and disease. Cytometry 1997;28:220-227.
48. Van den Hove LE, Vandenberghe P, Van Gool SW, et al. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: Evidence tor systemic activation of the T cell compartment. Leukemia Res 1998;22:175-184.
49. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD57+/ CD28-T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia 1998;12:1573-1582.
50. Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue antigens 1996;47:382-390.
51. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177: 265-272.
52. Koch N, Harris A. Differential expression of the invariant chain in mouse tumor cells: relationship to B lymphoid development. J Immunol 1984;132:12-15.
53. Becker JC, Brabletz T, Czerny C, et al. Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ T cell clone by the autologous MHC class II+ melanoma. Int Immunol 1993;5:1501-1508.
54. Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992;148:277-284.
55. Bodmer S, Huber D, Heid I, Fontana A. Human glioblastoma cell derived transforming growth factor-beta 2: evidence for secretion of both high and low molecular weight biologically active forms. J Neuroimmunol 1991;34:33-42.
56. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993; 92:2569-2576.
57. Yagita M, Seppo A, Renkonen O, Saksela E. Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity. Cancer Res 1993;53:5600-5604.
58. Li R, Gage D, Ladisch S. Biosynthesis and shedding of murine lymphoma gangliosides. Biochim Biophys Acta 1993;1170:283-290.
59. Bergelson LD. Gangliosides and antitumor immunity. Clin Investig 1993;71:590-594.
60. Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 1997;72:619-624.
61. O'Connell J, Bennett MW, O'Sullivan GC, et al. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
62. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736.
63. Van den Hove L, Van Gool SW, Vandenberghe P, et al. CD40-triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by upregulation of CD80 and CD86 costimulatory molecules. Leukemia 1997;11:572-580.
64. Delabie J, Ceuppens JL, Vandenberghe P, et al. The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993;82:2845-2852.
65. Van Gool SW, Delabie J, Vandenberghe P, et al. Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease. Leukemia 1997;11:846-851.
66. Huang AYC, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
67. Grabbe S, Beissert S, Schwarz T, Granstein RD. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995;16:117-120.
68. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997;186:1183-1187.
69. Mulders P, Tso C-L, Gitlitz B, et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999;5:445-454.
70. Baskar S, Glimcher L, Nabavi N, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:619-629.
71. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen-presenting cells. Proc Natl Acad Sci USA 1995;92:8078-8082.
72. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
73. Murphy G, Tjoa B, Ragde H, et al. A phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
74. Höltl L, Rieser C, Papesh C, et al. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 1998;352:1385.
75. Höltl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendrilic cells. J Urol 1999;161: 777-782.